Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-19.28%
0%
-19.28%
6 Months
1.54%
0%
1.54%
1 Year
-32.48%
0%
-32.48%
2 Years
42.82%
0%
42.82%
3 Years
-38.1%
0%
-38.1%
4 Years
-11.67%
0%
-11.67%
5 Years
-67.52%
0%
-67.52%
Diamyd Medical AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-4.61%
EBIT Growth (5y)
-283.27%
EBIT to Interest (avg)
-73.15
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.84
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
11.49%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.45
EV to EBIT
-6.95
EV to EBITDA
-7.20
EV to Capital Employed
27.04
EV to Sales
1294.22
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-389.22%
ROE (Latest)
-60.45%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - May'25 - YoY
May'25
May'24
Change(%)
Net Sales
0.00
0.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-47.50
-39.90
-19.05%
Interest
0.80
0.00
Exceptional Items
-0.50
0.00
Consolidate Net Profit
-43.90
-40.10
-9.48%
Operating Profit Margin (Excl OI)
0.00%
-794,384.60%
79,438.46%
USD in Million.
Net Sales
YoY Growth in quarter ended May 2025 is -100.00% vs 0.00% in May 2024
Consolidated Net Profit
YoY Growth in quarter ended May 2025 is -9.48% vs -94.66% in May 2024
Annual Results Snapshot (Consolidated) - Aug'24
Aug'24
Aug'23
Change(%)
Net Sales
0.10
0.50
-80.00%
Operating Profit (PBDIT) excl Other Income
-144.90
-112.70
-28.57%
Interest
0.00
0.00
Exceptional Items
-9.80
0.00
Consolidate Net Profit
-151.80
-116.10
-30.75%
Operating Profit Margin (Excl OI)
-1,198,784.60%
-215,313.20%
-98,347.14%
USD in Million.
Net Sales
YoY Growth in year ended Aug 2024 is -80.00% vs 0.00% in Aug 2023
Consolidated Net Profit
YoY Growth in year ended Aug 2024 is -30.75% vs -12.17% in Aug 2023
About Diamyd Medical AB 
Diamyd Medical AB
Pharmaceuticals & Biotechnology
Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.
Company Coordinates 
Company Details
Kungsgatan 29 , STOCKHOLM None : 111 56
Registrar Details






